Take drug, patient-level factors into account for when to end antiresorptive therapy

LAS VEGAS – The agent and individual patient factors may affect the duration of treatment and the approach to resuming therapy.

Guide to the guidelines: Biologics for psoriasis

Dr. April Armstrong highlights key messages in the AAD’s guidelines for the use of biologics to treat psoriasis.

Ixekizumab psoriasis outcomes, sliced and diced

WAIKOLOA, HAWAII – The jaw-dropping NNT to achieve complete skin clearance: 2.6 patients.

What’s new with adalimumab? Plenty

WAIKOLOA, HAWAII – New information includes reassuring new long-term, real-world safety data, plus a simple early predictor of PASI 75 response.

Guselkumab tops secukinumab over 48 weeks for plaque psoriasis

CAYMAN ISLANDS – In both groups, the PASI 90 increased similarly in the first month, but was consistently higher in the guselkumab group at week 12 and after.

Topical treatments remain a good option for psoriasis

LAS VEGAS – Creams and ointments still have a role, even in the age of biologics.

Comorbidities are important in psoriasis care

LAS VEGAS – Cardiovascular comorbidities and psoriatic arthritis top the list of issues to keep an eye on.

PsA and difficult-to-treat areas are common among patients with psoriasis

And more top psoriasis posters from the Las Vegas Dermatology Seminar

IL inhibitor options move psoriasis treatment forward

Long-term data continue to support the safety and effectiveness of IL-17 and IL-23 inhibitor drugs.

Patient outcome questionnaires take a beating in talk

LAS VEGAS – Too many patient-reported outcome surveys don’t ask the right questions, but there’s a good alternative, says Clifton O. Bingham III, MD.

Pages